Achillion Pharmaceuticals (Achillion Pharmaceuticals) EV-to-EBITDA : -12.98 (As of Apr. 27, 2024)

Achillion Pharmaceuticals EV-to-EBITDA Chart

Achillion Pharmaceuticals Annual Data
	Trend	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18
EV-to-EBITDA		Get a 7-Day Free Trial					-16.30	-237.26	-3.32	-1.16	0.73

Achillion Pharmaceuticals Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
EV-to-EBITDA	Get a 7-Day Free Trial															-3.01	0.73	-2.35	-2.02	-4.83

Competitive Comparison of Achillion Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Achillion Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Achillion Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achillion Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Achillion Pharmaceuticals's EV-to-EBITDA falls into.

Achillion Pharmaceuticals EV-to-EBITDA Calculation

Achillion Pharmaceuticals's EV-to-EBITDA for today is calculated as:

Achillion Pharmaceuticals's current Enterprise Value is $947.02 Mil.
Achillion Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-72.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Achillion Pharmaceuticals  (NAS:ACHN) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Achillion Pharmaceuticals's PE Ratio for today is calculated as:

Achillion Pharmaceuticals's share price for today is $6.76.
Achillion Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.540.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Achillion Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Achillion Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Achillion Pharmaceuticals (Achillion Pharmaceuticals) Business Description